Literature DB >> 18723841

Gene-environment interplay between cannabis and psychosis.

Cécile Henquet1, Marta Di Forti, Paul Morrison, Rebecca Kuepper, Robin M Murray.   

Abstract

Cannabis use is considered a contributory cause of schizophrenia and psychotic illness. However, only a small proportion of cannabis users develop psychosis. This can partly be explained by the amount and duration of the consumption of cannabis and by its strength but also by the age at which individuals are first exposed to cannabis. Genetic factors, in particular, are likely to play a role in the short- and the long-term effects cannabis may have on psychosis outcome. This review will therefore consider the interplay between genes and exposure to cannabis in the development of psychotic symptoms and schizophrenia. Studies using genetic, epidemiological, experimental, and observational techniques will be discussed to investigate gene-environment correlation gene-environment interaction, and higher order interactions within the cannabis-psychosis association. Evidence suggests that mechanisms of gene-environment interaction are likely to underlie the association between cannabis and psychosis. In this respect, multiple variations within multiple genes--rather than single genetic polymorphisms--together with other environmental factors (eg, stress) may interact with cannabis to increase the risk of psychosis. Further research on these higher order interactions is needed to better understand the biological pathway by which cannabis use, in some individuals, may cause psychosis in the short- and long term.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723841      PMCID: PMC2632498          DOI: 10.1093/schbul/sbn108

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  101 in total

1.  The structure of schizotypy: a pilot multitrait twin study.

Authors:  K S Kendler; A L Ochs; A M Gorman; J K Hewitt; D E Ross; A F Mirsky
Journal:  Psychiatry Res       Date:  1991-01       Impact factor: 3.222

2.  Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population.

Authors:  M Konings; M Bak; M Hanssen; J van Os; L Krabbendam
Journal:  Acta Psychiatr Scand       Date:  2006-07       Impact factor: 6.392

3.  Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population.

Authors:  M Hanssen; L Krabbendam; M Vollema; P Delespaul; J Van Os
Journal:  J Abnorm Psychol       Date:  2006-02

Review 4.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis.

Authors:  Jin-Bo Fan; Chang-Shun Zhang; Niu-Fan Gu; Xing-Wang Li; Wei-Wei Sun; Hong-Yan Wang; Guo-Yin Feng; David St Clair; Lin He
Journal:  Biol Psychiatry       Date:  2005-01-15       Impact factor: 13.382

5.  Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders.

Authors:  Melanie C M Appels; Margriet M Sitskoorn; Meinte G Vollema; René S Kahn
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

7.  Genetic and environmental contributions to cannabis dependence in a national young adult twin sample.

Authors:  M T Lynskey; A C Heath; E C Nelson; K K Bucholz; P A F Madden; W S Slutske; D J Statham; N G Martin
Journal:  Psychol Med       Date:  2002-02       Impact factor: 7.723

8.  Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study.

Authors:  H Verdoux; C Gindre; F Sorbara; M Tournier; J D Swendsen
Journal:  Psychol Med       Date:  2003-01       Impact factor: 7.723

9.  Gene-gene interaction associated with neural reward sensitivity.

Authors:  Juliana Yacubian; Tobias Sommer; Katrin Schroeder; Jan Gläscher; Raffael Kalisch; Boris Leuenberger; Dieter F Braus; Christian Büchel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

Review 10.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

View more
  64 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

3.  Genetic predisposition to schizophrenia associated with increased use of cannabis.

Authors:  R A Power; K J H Verweij; M Zuhair; G W Montgomery; A K Henders; A C Heath; P A F Madden; S E Medland; N R Wray; N G Martin
Journal:  Mol Psychiatry       Date:  2014-06-24       Impact factor: 15.992

4.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

Review 5.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 6.  Cannabis controversies: how genetics can inform the study of comorbidity.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

7.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

8.  Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable?

Authors:  David Kimhy; Kelly Durbin; Cheryl M Corcoran
Journal:  Prim psychiatry       Date:  2009

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

10.  Predictors of a clinical high risk status among individuals with a family history of psychosis.

Authors:  Jacqueline Stowkowy; Jean Addington
Journal:  Schizophr Res       Date:  2013-04-20       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.